Does PTAB’s Ex Parte Cellect Decision Endanger Biopharmaceutical Patent Terms? – Mayer Brown

… double patenting by the US Patent Trial and Appeal Board (“PTAB”) in Ex Parte Cellect. This Legal Update explores how the PTAB arrived at it.